PsoBest - The German Psoriasis Registry

Summary

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time. The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.

Conditions

• Psoriasis
• Psoriatic-arthritis

Sponsors & Collaborators

• Berufsverband der Deutschen Dermatologen e.V. (www.bvdd.de)

  collaborator UNKNOWN

• Deutsche Dermatologische Gesellschaft e.V. (https://derma.de)

  collaborator UNKNOWN

• AbbVie

  collaborator INDUSTRY

• Biogen

  collaborator INDUSTRY

• Janssen-Cilag G.m.b.H

  collaborator INDUSTRY

• medac GmbH

  collaborator INDUSTRY

• Merck Sharp & Dohme LLC

  collaborator INDUSTRY

• Novartis Pharmaceuticals

  collaborator INDUSTRY

• Pfizer Pharmaceuticals Ltd.

  collaborator INDUSTRY

• Merck Serono GmbH, Germany

  collaborator INDUSTRY

• PsoNet.eu (http://www.psonet.eu/)

  collaborator UNKNOWN

• Celgene

  collaborator INDUSTRY

• Eli Lilly and Company

  collaborator INDUSTRY

• Amgen

  collaborator INDUSTRY

• Almirall Hermal GmbH

  collaborator INDUSTRY

• UCB Pharma

  collaborator INDUSTRY

• Bristol-Myers Squibb

  collaborator INDUSTRY

• Viatris Inc.

  collaborator INDUSTRY

• LEO Pharma

  collaborator INDUSTRY

• Universitätsklinikum Hamburg-Eppendorf

  lead OTHER

Principal Investigators

• Matthias Augustin, Prof. Dr. · Universitätsklinikum Hamburg-Eppendorf

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-01-31

Primary Completion

2032-12-31

Completion

2032-12-31

Countries

• Germany

Study Locations